diseases-developing-treatment-31.html
Novo Annual Review 2016
32 / 71
investing in next generation oncology therapies fig. 1
immune
cell
-driven tumour
cell
killing involves multiple processes and
cell
types: 1) natural killer
cell
-mediated killing; 2) cytotoxic t-
cell
mediated killing; 3) engineered antibodies such as bi-specific antibodies that engage the tumour
cell
directly; 4) genetically engineered t-
cell
s targeting tumour-specific antigens (e.g., car-t); and 5) macrophage-mediated phagocytosis. companies in the novo ventures portfolio represent each of these approaches. target
cancer
cell
genetically engineered t
cell
ar
cell
x macrophage tioma bispecific antibody merus activated t corvus, rgenix nk
cell
nkarta one of the significant breakthroughs within
cancer
research is immuno-oncology ? using the body?s own
immune
system to fight
cancer
. novo a/s has made several investments in immuno- oncology companies, providing capital and support to transform innovative research into therapies that work. i mmuno-oncology is the principle by which a patient?s
immune
system attacks and clears malignant
cell
s. recent clinical advances have demonstrated that pharmacological interventions ? through mechanisms that lead to the activation of
immune
cell
s ? can control certain
cancer
s (fig. 1). emerging data indicate that multiple
immune
cell
types as well as numerous
immune
-suppressive pathways represent therapeutic opportunities to induce synergistic anti-tumour responses. however, researchers need to push a number of scientific and clinical frontiers. these include developing strategies for neutralising tumour-promoting processes, broadening the repertoires of harmful antigens recognised by our
immune
systems, and targeting the mechanisms by which
immune
cell
s recognise and attack tumour tissues in particular. such efforts are expected to pave the way for developing novel therapies that overcome resistance to current treatments and promote long-term control of
cancer
. our investments over recent years are creating opportunities that will impact the treatment of
cancer
in the future. 32 novo a/s 2016
immune-cells-cell-33.html
